Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: FASEB J. 2019 Dec 4;34(1):1679–1694. doi: 10.1096/fj.201900567RR

FIGURE 2.

FIGURE 2

CSF1R and CSF-1 protein levels are increased in the nigrostriatal pathway following neurotoxicant treatment. A and B, Increased protein level of CSF1R in the mouse striatum was treated with LPS by western blotting (A) and SN by immunofluorescent microscopy (B) (20× magnification, scale bar 50 μm). C and D, Increased protein level of CSF1R in the mouse striatum was treated with MPTP by western blotting (C) and SN by immunofluorescent microscopy (D) (20× magnification, scale bar 50 μm). E and F, Increased protein level of CSF-1 in the mouse striatum was treated with MPTP by western blotting (E) and representative immunofluorescent microscopy images (F; 10× magnification, scale bar 40 μm) for CSF-1 (green) levels and Iba1-positive (red) cells of the SN following either saline or MPTP treatment. All data are presented as means ± SEM; n = 2–4 mice per group; *P < .05, **P < .01 and ***P < .001